<code id='B368F400E0'></code><style id='B368F400E0'></style>
    • <acronym id='B368F400E0'></acronym>
      <center id='B368F400E0'><center id='B368F400E0'><tfoot id='B368F400E0'></tfoot></center><abbr id='B368F400E0'><dir id='B368F400E0'><tfoot id='B368F400E0'></tfoot><noframes id='B368F400E0'>

    • <optgroup id='B368F400E0'><strike id='B368F400E0'><sup id='B368F400E0'></sup></strike><code id='B368F400E0'></code></optgroup>
        1. <b id='B368F400E0'><label id='B368F400E0'><select id='B368F400E0'><dt id='B368F400E0'><span id='B368F400E0'></span></dt></select></label></b><u id='B368F400E0'></u>
          <i id='B368F400E0'><strike id='B368F400E0'><tt id='B368F400E0'><pre id='B368F400E0'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:5726
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Let's speed up science by embracing open access publishing
          Let's speed up science by embracing open access publishing

          APStockSixyearsago,HarvardscientistJayBradnerdiscoveredsomethingunusual.Hislaboratoryhadisolatedamol

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Study suggests Covid rebound is far more common with Paxlovid than without

          AdobeAsmallandpreliminarystudypublishedMondayseemstoindicatethatpatientsreceivingthedrugPaxlovidaref